ProKidney Corp. (PROK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProKidney Corp. (PROK) has a cash flow conversion efficiency ratio of -0.108x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.51 Million) by net assets ($300.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ProKidney Corp. (PROK) defensive interval to measure how many days the company can operate on defensive assets alone.
ProKidney Corp. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how ProKidney Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
ProKidney Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProKidney Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
King Core Electronics Inc
TW:6155
|
0.045x |
|
Orrön Energy AB (publ)
ST:ORRON
|
-0.001x |
|
Magnora ASA
OL:MGN
|
-0.119x |
|
Rane Holdings Limited
NSE:RANEHOLDIN
|
0.042x |
|
Springsnow Food Group Co Ltd
SHG:605567
|
0.062x |
|
The Korea Fund Inc
F:KOF1
|
N/A |
|
Qinhuangdao Port Co Ltd
F:QHD
|
0.040x |
|
Exicom Tele-Systems Limited
NSE:EXICOM
|
-0.084x |
Annual Cash Flow Conversion Efficiency for ProKidney Corp. (2019–2025)
The table below shows the annual cash flow conversion efficiency of ProKidney Corp. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see PROK company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $300.79 Million | $-120.12 Million | -0.399x | -26.94% |
| 2024-12-31 | $401.64 Million | $-126.35 Million | -0.315x | -36.68% |
| 2023-12-31 | $391.34 Million | $-90.07 Million | -0.230x | -50.76% |
| 2022-12-31 | $504.94 Million | $-77.09 Million | -0.153x | +91.83% |
| 2021-12-31 | $26.92 Million | $-50.30 Million | -1.869x | +26.80% |
| 2020-12-31 | $9.86 Million | $-25.18 Million | -2.553x | -52690.69% |
| 2019-12-31 | $15.88 Million | $-76.81K | -0.005x | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more